A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapy

Blood

Volumn 113, Issue 17, 2009, Pages 3891-3895

  Sharkey, Robert M ^a   Press, Oliver W ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CD20 ANTIBODY; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; VELTUZUMAB; YTTRIUM 90; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY;

BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG TARGETING; DRUG UPTAKE; HODGKIN DISEASE; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; ANIMAL; ARTICLE; CHEMISTRY; IMMUNOLOGY; NONHODGKIN LYMPHOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY;

EID: 65449177689     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2008-11-188896     Document Type: Review

References (51)

1. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978;298:1384-1386. (Pubitemid 8358628)
2. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46:115S-127S.
3. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
4. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463. (Pubitemid 34525730)
5. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576-4582.
6. 131 tositumomab. Oncogene. 2007;26:3614-3628.
7. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:629-636. (Pubitemid 43753373)
8. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573.
9. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stemcell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25:1396-1402.
10. Kaminski MS, Radford JA, Gregory SA, et al. Retreatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23:7985-7993.
11. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:90-95.
12. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol. 2008;9:352-358.
13. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54-58. (Pubitemid 47026818)
14. 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment. Lancet Oncol. 2007;8:849-850.
15. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-4149.
16. Shah J, Wang W, Harrough VD, et al. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2007;48:1736-1744. (Pubitemid 47386709)
17. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810. (Pubitemid 46668544)
18. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008;19:769-773.
19. Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer. 2008;112:856-862. (Pubitemid 351246571)
20. Press OW. Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. J Clin Oncol. 2008;26:5147-5150.
21. 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl. 1988;3:96-101.
22. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. J Nucl Med. 1990;31:1257-1268.
23. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696-1711.
24. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038. (Pubitemid 19196525)
25. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224. (Pubitemid 23306322)
26. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
27. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
28. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med. 1998;39:21S-27S.
29. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470. (Pubitemid 26100047)
30. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
31. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. 1992;52:6476-6481.
32. Skvortsova I, Popper BA, Skvortsov S, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo). 2005;46:241-248. (Pubitemid 41190661)
33. Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and -independent mechanisms. J Radiat Res (Tokyo). 2006;47:183-196. (Pubitemid 44034037)
34. Kapadia NS, Engles JM, Wahl RL. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med. 2008;49:674-678.
35. Rupnow BA. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis. 1999;4:115-143.
36. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792-7798.
37. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but no radiolabeled anti-CD45-Ab. Blood. 2008;112:830-835.
38. Food and Drug Administration Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Center for Drug Evaluation and Research (CDER), Pharmacology and Toxicology. July 2005;1-27.
39. Sharkey RM, Karacay H, Johnson CR, et al. Pretargeted vs. directly targeted radioimmunotherapy with anti-CD20 antibody consolidation of non-Hodgkin lymphoma in a nude mouse model. J Nucl Med. 2009;50:444-453.
40. 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res. 2008;14:6154-6160.
41. 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113:1412-1421.
42. 90Y [abstract]. J Clin Oncol. 2008;26:454S. Abstract 8502.
43. 90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000-2018.
44. 111In- ibritumomab pretreatment imaging. J Nucl Med. 2008;49:1809-1812.
45. 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med. 2005;46:1812-1818.
46. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156-5164.
47. Pagel JM, Hedin N, Drouet L, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood. 2008;111:2261-2268.
48. Pagel JM, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 2003;101:2340-2348. (Pubitemid 36302079)
49. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
50. Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia. 2005;19:1064-1069. (Pubitemid 40862020)
51. Sharkey RM, Karacay H, Litwin S, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68:5282-5290.